2. Academic Validation
  3. Discovery, oral pharmacokinetics and in vivo efficacy of velusetrag, a highly selective 5-HT(4) receptor agonist that has achieved proof-of-concept in patients with chronic idiopathic constipation

Discovery, oral pharmacokinetics and in vivo efficacy of velusetrag, a highly selective 5-HT(4) receptor agonist that has achieved proof-of-concept in patients with chronic idiopathic constipation

  • Bioorg Med Chem Lett. 2012 Oct 1;22(19):6048-52. doi: 10.1016/j.bmcl.2012.08.051.
Daniel D Long 1,  Scott R Armstrong,  David T Beattie,  Seok-Ki Choi,  Paul R Fatheree,  Roland A L Gendron,  Daniel Genov,  Adam A Goldblum,  Patrick P Humphrey,  Lan Jiang,  Daniel G Marquess,  Jeng-Pyng Shaw,  Jacqueline A M Smith,  S Derek Turner,  Ross G Vickery
Affiliations

Affiliation

  • 1 Theravance, Inc., 901 Gateway Blvd, South San Francisco, CA 94080, United States. dlong@theravance.com
PMID: 22959244 DOI: 10.1016/j.bmcl.2012.08.051
Abstract

Utilization of Theravance's multivalent approach to drug discovery towards 5-HT(4) receptor agonists with a focus on identification of neutral (non-charged at physiological pH) secondary binding groups is described. Optimization of a quinolone-tropane primary binding group with a chiral 2-propanol linker to a range of neutral secondary binding group motifs, for binding affinity and functional potency at the 5-HT(4) receptor, selectivity over the 5-HT(3) receptor, oral pharmacokinetics, and in vivo efficacy in models of GI motility, afforded velusetrag (TD-5108). Velusetrag has achieved proof-of-concept in patients with chronic idiopathic constipation.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z